Pipeline - Proprietary Pharmaceuticals
Abbott is dedicated to bringing to market medicines that demonstrate strong clinical performance, patient benefit and economic value. The following are highlights of key programs in our proprietary pharmaceutical pipeline:
Chronic Kidney Disease
Current treatments of chronic kidney disease (CKD) only modestly slow its progression, with many patients ultimately progressing to end-stage kidney disease requiring dialysis. Bardoxolone, a novel therapy in Phase 3 development with a partner, is a promising treatment for CKD that has the potential to slow the progression to dialysis. Also in development for the treatment of CKD is atrasentan, a compound discovered by Abbott scientists. An atrasentan study in patients with diabetic kidney disease is ongoing.
Parkinson’s disease, a chronic and progressive brain disorder, leads to tremors, muscle rigidity, slowness of movement and difficulty with balance. The disease affects approximately 5 million people worldwide. We’re developing an intestinal gel with a unique delivery system that delivers two compounds with promising results in advanced Parkinson’s disease. It is currently in Phase 3 development and on the market in select countries outside the United States.
Multiple Sclerosis (MS), a chronic disease in which the body’s own immune system attacks the nervous system, affects approximately 2 million people worldwide. Daclizumab, a next-generation biologic in Phase 3 development with a partner, has the potential to provide an impactful new treatment option for MS patients from both a safety and efficacy perspective. In our neuroscience pipeline, Abbott has a number of compounds in human studies for conditions such as schizophrenia, pain, Alzheimer’s disease, Parkinson’s disease and MS.
We’re investigating unique scientific approaches to treating cancer and are focused on the development of targeted treatments that inhibit tumor growth and improve response to common cancer therapies. Our oncology pipeline includes a number of molecules in clinical development for different cancer types. For instance, we’re studying elotuzumab in patients with multiple myeloma through a research partnership. Our PARP (Poly (ADP-ribose) polymerase) inhibitor in development is being studied in breast cancer and a number of additional varieties of cancer. In addition, Abbott has pioneered the discovery and development of selective inhibitors of Bcl-2 for the treatment of hematological cancers.
More than 350,000 people are estimated to die from hepatitis C-related liver diseases each year. Our investigational therapies for hepatitis C (HCV) have the potential to dramatically change today’s treatment landscape. Abbott’s broad-based HCV program includes three mechanisms of action in clinical trials, including protease, polymerase and NS5A inhibitors. Phase 2 data regarding our drug combination targeting different HCV enzymes have indicated the opportunity for very high cure rates in hepatitis C patients with a simpler and shorter course of therapy.